PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
74.78%
Positive EBIT growth while GNPX is negative. John Neff might see a substantial edge in operational management.
74.78%
Positive operating income growth while GNPX is negative. John Neff might view this as a competitive edge in operations.
64.85%
Positive net income growth while GNPX is negative. John Neff might see a big relative performance advantage.
64.71%
EPS growth above 1.5x GNPX's 34.62%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
64.71%
Diluted EPS growth above 1.5x GNPX's 34.62%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-60.52%
Negative OCF growth while GNPX is at 7.14%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-60.52%
Negative FCF growth while GNPX is at 7.14%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
51.61%
10Y OCF/share CAGR at 50-75% of GNPX's 91.62%. Martin Whitman might fear a structural deficiency in operational efficiency.
51.61%
5Y OCF/share CAGR at 50-75% of GNPX's 96.48%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
51.61%
3Y OCF/share CAGR at 50-75% of GNPX's 96.26%. Martin Whitman would suspect weaker recent execution or product competitiveness.
66.06%
Net income/share CAGR at 50-75% of GNPX's 99.56%. Martin Whitman might question if the firm’s product or cost base lags behind.
66.06%
5Y net income/share CAGR at 50-75% of GNPX's 96.58%. Martin Whitman might see a shortfall in operational efficiency or brand power.
66.06%
3Y net income/share CAGR 50-75% of GNPX's 96.48%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.06%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-5.28%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
11.50%
Debt growth of 11.50% while GNPX is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
-73.61%
We cut SG&A while GNPX invests at 52.68%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.